A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

  • End date
    Jun 28, 2022
  • participants needed
  • sponsor
Updated on 4 June 2021
tubal ligation
trivalent influenza vaccine


Study to evaluate the safety and immunogenicity of H7N9 antigen in combination with full or half doses of AS03 adjuvant system in healthy adults.

Condition Influenza
Treatment Placebo, FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3, AS03B, AS03A
Clinical Study IdentifierNCT04789577
Last Modified on4 June 2021


Yes No Not Sure

Inclusion Criteria

Healthy participants as established by medical history and clinical examination before entering into the study
A male or female 18 years of age at the time of first vaccination
Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of the diary cards and COVID-19 assessment card, return for follow-up visits, or return the diary cards and COVID-19 assessment card in a timely manner using the pre stamped envelope received at the site)
Written or witnessed/thumb printed informed consent obtained from the participant prior to performance of any study specific procedure
Female participants of non-childbearing potential may be enrolled in the study. Non childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion hysterectomy, bilateral ovariectomy or post-menopause
Female participants of childbearing potential may be enrolled in the study, if the
has practiced adequate contraception for 1 month prior to vaccination, and
has a negative pregnancy test on the day of vaccination, and
has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series

Exclusion Criteria

Current diagnosis or history of autoimmune disorder(s)
History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine
Hypersensitivity to latex
Acute or chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality that appears uncontrolled, as determined by history or physical examination
Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required)
Recurrent history or uncontrolled neurological disorders or seizures
History of Guillain-Barr syndrome
Diagnosed with narcolepsy; or history of narcolepsy in a participant's parent, sibling or child
Diagnosed with cancer, or treatment for cancer within 3 years
Persons with a history of cancer who are disease-free without treatment for 3 years or more are eligible
Persons with a history of histologically-confirmed basal cell carcinoma of the skin successfully treated with local excision only are accepted and are eligible, but other histologic types of skin cancer are exclusionary
Women who are disease-free 3 years or more after treatment for breast cancer and receiving long-term prophylaxis (for example, with tamoxifen) are eligible
Documented human immunodeficiency virus-positive participant
Any clinically significant hematological laboratory abnormality
The investigator should use his/her clinical judgement to decide which abnormalities are clinically significant
Bedridden participants
Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study
Use of any investigational or non-registered product (drug, vaccine or medical device) other than the study vaccine/product during the period beginning 30 days before the first dose of study vaccine/product (Day -29 to Day 1), or planned use during the study period
Administration of long-acting immune-modifying drugs at any time during the study period (e.g. infliximab)
Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the first dose of study vaccine/product or planned administration during the study period
Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first vaccine/product dose. For corticosteroids, this will mean prednisone equivalent 20 mg/day. Inhaled and topical steroids are allowed
Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (drug or medical device)
Pregnant or lactating female
Female planning to become pregnant or planning to discontinue contraceptive precautions within 2 months after completion of the vaccination series
History of or current chronic alcohol consumption and/or drug abuse
Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study
Any study personnel or immediate dependents, family, or household member
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note